Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT03961347
PHASE2

Lactobacillus Johnsonii Supplementation in Adults With T1D

Sponsor: University of Florida

View on ClinicalTrials.gov

Summary

While genetics demonstrated a major risk factor for the development of type 1 diabetes (T1D), microbiota dysbiosis has been suggested as an elicitor in immunological tolerance and of beta cell autoimmunity. The probiotic Lactobacillus johnsonii N6.2 may prevent or restore the gut flora and show systemic impacts and adaptive immunity in the T1D population thereby preserving beta cell function.

Official title: Evaluation of Safety, Tolerability and Immunological Responses to Lactobacillus Johnsonii N6.2 Supplementation in Adults With Diabetes Type 1

Key Details

Gender

All

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

46

Start Date

2020-02-01

Completion Date

2026-03-18

Last Updated

2026-03-12

Healthy Volunteers

No

Interventions

DRUG

L. johnsonii Probiotic

Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.

DRUG

Placebo Capsule

Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.

Locations (1)

UF Clinical Research Center

Gainesville, Florida, United States